Abstract: TH-PO903

Circulating Interferon-λ3, HBV Vaccination, and HBV/HCV Infections in Hemodialysis Patients

Session Information

  • Dialysis: Infection
    November 02, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 610 Dialysis: Infection

Authors

  • Grzegorzewska, Alicja E., Poznan University of Medical Sciences (PUMS), Poznan, Poland
  • Swiderska, Monika K., PUMS, Poznan, Poland
  • Mostowska, Adrianna, PUMS, Poznan, Poland
  • Jagodzinski, Pawel P., PUMS, Poznan, Poland
Background

Interferon (IFN)-λ3 gene (IFNL3) is known from its crucial role in HCV clearance. Our aim was to investigate circulating IFN-λ3 and single nucleotide polymorphisms (SNPs) of IFNL3 in hemodialysis (HD) patients who differed in response to HBV vaccination and status of HBV/HCV infections.

Methods

In 201 HD patients and 28 controls, plasma IFN-λ3 (ng/L) was determined using ELISA. IFNL3 SNPs (rs12979860, rs8099917) were genotyped using HRM analysis.

Results

HBV vaccine responders among HD patients showed higher IFN-λ3 than healthy responders (120, 36–233 vs 62, 12.3–280, P=0.0004). In HD group, significant differences in circulating IFN-λ3 were shown between responders and non-responders to HBV vaccination (120, 36–233 vs 43, 15.9–77.4, P=1.0E-7) as well as between HBsAg positive patients and those who developed anti-HBs and became HBsAg negative after HBV infection (39.1, 10–83.4 vs 125, 35–215, P=0.010). Responders to HBV vaccination, who resolved HCV infection, did not differ in circulating IFN-λ3 from non-infected responders (133, 14.8–400 vs 120, 36–233, P=0.714), whereas responders to HBV vaccination, who did not show spontaneous HCV resolution, revealed lower IFN-λ3 than non-infected responders (74, 4.9–275 vs 120, 36–233, P=0.013). In patients with both infections, HBsAg positive/HCV RNA positive subjects showed lower IFN-λ3 (13.3, 9–21.6) than only HCV RNA positive patients (57.5, 13.7–203, P=0.031) and lower compared with patients who resolved both infections (88.5, 16.0–300, P=0.020). Circulating IFN-λ3 showed independent positive association with anti-HBs titer (β±SE 8.4±1.1, P=4.0E-13) and negative associations with HCV RNA (β±SE -32.5±11.4, P=0.005) and HBsAg (β±SE -45.3±22.9, P=0.049) positivity. Non-responders to HBV vaccination, patients HBsAg positive, and subjects replicating HCV composed a group with unfavorable outcomes. The remaining patients were analyzed as having favorable outcomes. The latter showed higher IFN-λ3 (120, 14.8–400 vs 50.7, 4.9–275, P=1.0E-11), but did not differ in distribution of IFNL3 SNPs compared with subjects with unfavorable outcomes.

Conclusion

Higher IFN-λ3 concentrations are associated with response to HBV vaccination, self-limited HBV infection, and spontaneous HCV resolution.